Therapy with ALK-positive non-small cell lung cancer: reality and prospects


Cite item

Full Text

Abstract

There is highlighted special small subgroup of patients with non-small cell lung cancer who has translocation of gene ALK in tumor. The modified gene encodes a fusion of pathological protein, leading to activation of ALK receptor on the membrane of tumor cells and then malignant transformation. Clinical studies of crizotinib noted a high frequency (> 60%) of complete and partial responses in chemoresistant metastatic ALK-positive lung cancer; median of progression-free survival reached more than 9 months. Crizotinib is the ATP competitive inhibitor of tyrosine kinase receptor like ALK, MET and ROS1, is one of the most effective drugs for the treatment ofALK-positive lung cancer. However, it is almost inevitable that almost all patients, even in the most pronounced immediate effect to 24 months of treatment crizotinib marked progression of the disease, which is associated with the development of tumor resistance. Currently, clinical studies of the second generation inhibitors of tyrosine kinases, such as ceritinib, alectinib, AP26113 etc, are continuing. Their application is possible in case of the development of resistance to crizotinib.

About the authors

V. V Breder

N.N. Blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

K. K Laktionov

N.N. Blokhin Russian Cancer Research Center

115478, Moscow, Russian Federation

Denis I. Yudin

N.N. Blokhin Russian Cancer Research Center

Email: yudinden@mail.ru
MD, Phd 115478, Moscow, Russian Federation

N. E Hamrina

A.I. Evdokimov Moscow State University of Medicine and Dentistry

127473, Moscow, Russian Federation

References

  1. Webb T.R., Slavish J., George R.E., Look A.T., Xue L., Jiang Q. et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev. Anticancer Ther. 2009; 9(3): 331-56.
  2. Le Beau M.M., Bitter M.A., Larson R.A. et al. The t(2;5) (p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma.” Leukemia, 1989; 3(12): 866-70.
  3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S. et al. Identification of the transforming EML4- ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561-6.
  4. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131(6): 1190-203.
  5. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immune-histochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer. Res. 2009; 15(9): 3143-9.
  6. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G. et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N. Engl. J. Med. 2010; 363(18): 1693703.
  7. Garber K. ALK, lung cancer, and personalized therapy: portent of the future. J. Natl Cancer Inst. 2010; 102(10): 672-5. doi: 10.1093/jnci/djq184
  8. Rodig S.J., Mino-Kenudson M., Dacic S.,Yeap B.Y., Shaw A., Barletta J.A. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 2009; 15: 5216-23.
  9. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27: 4247-53.
  10. Varella-Garcia M. et al. In: IASLC. 2011: Abstr. #O05.01
  11. Varella-Garcia M., Berry L.D., Su P.F., Frnklin W.A., Iafrate A.J., Ladanyi M. et al. ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience. In: ASCO. Annual. Meeting. 2012: Abstr. 7589.
  12. Atherly A.J., Camidge D.R. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br. J. Cancer. 2012; 106(6): 1100-6.
  13. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G. et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J. Thorac. Oncol. 2013. doi;10.1097/JTO.0b013e318290868f
  14. Lee J.K., Park H.S., Kim D.W. et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced non-small cell lung cancer. Cancer. 2011; 118: 3579-86.
  15. Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R. et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol 2012; 7: 90-7.
  16. Kim H.R., Shim H.S., Chung J.H., Lee Y.J., Hong Y.K., Rha S.Y. et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012; 118: 729-39.
  17. Zhang X., Zhang S., Yang X. et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol. Cancer. 2010; 9: Article 188.
  18. Huang W.-Ch. et al. Changes in molecular profile following platinum chemotherapy in NSCLC. In: ASCO, Annual Meeting. 2011; Abstr. 10518.
  19. Camidge D.R., Kono S.A., Flacco A., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010; 16(22): 5581-90.
  20. Thunnissen E., Bubendorf L., Dietel V., Elmberger G., Kerr K., Lopez-Rios F. еt al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461(3): 245-57.
  21. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J. еt al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16(5): 1561-71. doi: 10.1158/1078-0432.CCR-09-2845
  22. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H.et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J. Thorac. Oncol. 2011; 6: 1359-66.
  23. NCCN guidelines, ver. 2, 2013. www.nccn.org
  24. Ou S.H. et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2013; 31 (Suppl.): Abstr. 8032.
  25. Chu A.S. et al. Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. J. Clin. Oncol. 2012; 30 (Suppl.): Abstr. 2072.
  26. Lennerz J.K., Kwak E.L., Ackerman A., Michael M., Fox S.B., Bergethon K. et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 2011; 29: 4803-10.
  27. Butrynski J.E., D’Adamo D.R., Hornick J.L., Dal Cin P., Antonescu C.R., Jhanwar S.C. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 2010; 363(18): 1727-33.
  28. Stasia A. et al. Crizotinib obtains durable responses in advanced chemoresistant ALK+ lymphoma patients. Haematologica 2012; 97 (Suppl. 1): 488.
  29. Mosse Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14: 472-80.
  30. Tan W., Wilner K.D., Bang Y. et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J. Clin. Oncol. 2010; 28 (Suppl. 15): Abstr. 2596.
  31. Camidge D.R., Bang Y., Kwak E.L. et al. Progression-free survival from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer. J. Clin. Oncol. 2011; 29(Suppl): Abstr. 2501.
  32. Camidge D.R. Bang Y., Kwak E.L. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-9.
  33. Kim D.W. et al. Updated results of a global phase II study with crizotinib in Advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC). In: ESMO. Annual Meeting. 2012: abstr 1230PD
  34. Riely G.J., Evans T.L., Salgia R. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Paper presented at: the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology; September 6-8, 2012; Chicago, IL.
  35. Solomon B., Chiappori A., Lamb A., Gawlicki M.C., Kim D.W., Salgia R. et al. Preliminary Characterization of Visual Events Reported by Patients Receiving Crizotinib for the Treatment of Advanced ALK-positive Non-small Cell Lung Cancer. Eur. J. Cancer. 2011; 47: doi: 10.1016/S0959.8049(11)71103-0
  36. Shaw A.T., Kim D.-W., Nakagawa K. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013. doi: 10.1056/NEJMoa1214886.
  37. Mok T. et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J. Clin. Oncol. 2014; 32 (Suppl. 5): Abstr. 8002)
  38. Besse B., Salgia R., Solomon B. et al. Visual Disturbances in Patients (Pts) with Anaplastic Lymphoma Kinase (ALK)-positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib. ESMO. 2012; Abstr. 1268P
  39. Crino L., Kim D., Riely G.J., Janne P.A., Blackball F.H., Camidge D.R. et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 2011; 29 (Suppl): abstr 7514.
  40. Weickhardt A.J., Rothman M.S., Salian-Mehta S., Kiseljak-Vassiliades K., Oton A.B., Doebele R.C. et al. Rapid onset hypogonadism secondary to crizotinib use in men with metastatic non-small cell lung cancer. Cancer. 2013. doi: 10.1002/cncr.28089.
  41. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012; 9: 268-277. doi: 10.1038/nrclinonc.2012.43.
  42. Doebele R.C., Pilling A.B., Aisner D.L., Kutatetaladze T.G., Le A.T., Weickhardt A.J. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012; 18(5): 1472-82.
  43. Katayama R., Shaw A.T., Khan T.M. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012; 4(120): 120ra17.
  44. Katayama R., Khan T.M., Benes C. et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad Sci. USA. 2011; 108(18): 7535-40.
  45. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E. , Holmes A.J. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer. Res. 2008; 14(13): 4275-83.
  46. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., Wilner K.D. et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 2011; 29(15): e443-5.
  47. Ou S.I., Zhou C., Ahn M. et al. Treatment of ALK-positive nonsmall cell lung cancer patients with crizotinib beyond disease progression: clinical assessment and potential management implications. J. Thorac. Oncol. 2012; 7(Suppl. 5): S446, Aabstr. HO-005.
  48. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q. et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014; 370: 1189-97.
  49. Zhang S., Wang F., Keats J. et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem. Biol. Drug Des. 2011; 78(6): 999-1005.
  50. Heuckmann J.M., Holzel M., Sos M.L. et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res. 2011; 17(23): 7394-401.
  51. Camidge D.R., Bazhenova L., Salgia S. et al. First-in-human dose-finding of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. In: Program and Abstracts of the 2013 ASCO Annual Meeting. 2013: Abstr. 8031.
  52. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A. Lilenbaum R. et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 2010; 28(33): 4953-60.
  53. Wong K., Koczywas M., Goldman J.W., Pascold E.H., Horn L., Lufkin J.M. et al. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2011; 29 (Suppl.): Abstr. 7500.
  54. Camidge D.R., Kono S.A., Lu X., Okuyama S., Baron A.E., Oton A.B. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 2011; 6(4): 774-80.
  55. Lee J.O., Kim T.M., Lee S.H., Kim D.W., Kim S., Jeon Y.K. et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J. Thorac. Oncol. 2011; 6(9): 1474-80.
  56. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F. , von Pawel J. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-97.
  57. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Petrson P. et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist. 2009; 14: 253-63.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies